{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:06Z","timestamp":1788279966601,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate and compare the efficacy of different antidiabetic agents in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant randomized controlled trials up to April 20, 2025. Primary outcomes were alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triglycerides. Secondary outcomes included HDL, LDL, fasting plasma glucose (FPG), body mass index (BMI), and glycated hemoglobin (HbA1c). All statistical analyses were performed using R version 4.5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 randomized controlled trials were included, covering 15 antidiabetic agents and involving 1,717 participants. Ertugliflozin was the most effective in reducing ALT and AST levels, followed by pioglitazone and metformin for ALT, and pioglitazone and ipragliflozin for AST. Ertugliflozin also showed favorable effects on triglycerides, BMI, HDL, LDL, and liver stiffness. However, most comparisons did not reach statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ertugliflozin appears to be among the most effective treatment options for improving liver function and metabolic parameters in patients with MASLD and T2DM. However, these findings should be interpreted with caution, and further high-quality studies are needed to confirm these results. Ertugliflozin may be the most effective option for improving liver function and metabolic parameters in patients with MASLD and T2DM. Further studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1659740","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:52:05Z","timestamp":1767768725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xin","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XianHong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0130","article-title":"Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"46","author":"Seo","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12916-024-03315-0","article-title":"Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis","volume":"22","author":"Cao","year":"2024","journal-title":"BMC Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251322002","article-title":"Therapeutic potential of GLP-1 receptor agonists in metabolic associated steatotic liver disease","volume":"59","author":"Nowak","year":"2025","journal-title":"Ann Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14846","article-title":"Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity","author":"Schr\u00f6der","year":"2021","journal-title":"Liver Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12856","article-title":"Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus","volume":"47","author":"Sumida","year":"2017","journal-title":"Hepatol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis","volume":"23","author":"Panunzi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0137","article-title":"Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease","volume":"26","author":"Kim","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e13335","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int J Clin Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","article-title":"Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial","volume":"23","author":"Attaran","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-014-0638-3","article-title":"Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes","volume":"51","author":"Bi","year":"2014","journal-title":"Acta Diabetol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho","year":"2021","journal-title":"J Diabetes Investig"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302013000900005","article-title":"Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease","volume":"57","author":"Fan","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial","volume":"10","author":"Feng","year":"2019","journal-title":"J Diabetes Investig"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12080186","article-title":"Therapeutic effects of semaglutide on nonalcoholic fatty liver disease with type 2 diabetes mellitus and obesity: an open-label controlled trial","volume":"12","author":"Gad","year":"2024","journal-title":"Diseases"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e40356","DOI":"10.1097\/MD.0000000000040356","article-title":"The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial","volume":"103","author":"Khaliq","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12902-025-01882-8","article-title":"The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"25","author":"Shojaei","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: A randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181304","article-title":"Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.01.007","article-title":"Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"44","author":"Zhang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-025-03902-w","article-title":"The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease","volume":"20","author":"Amin","year":"2025","journal-title":"Intern Emerg Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial","volume":"24","author":"Ferreira","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-018-0134-2","article-title":"Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"33","author":"Zhao","year":"2019","journal-title":"J Hum Hypertens"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01176.x","article-title":"The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41598-022-27301-9","article-title":"Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study","volume":"13","author":"Nagao","year":"2023","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00907-w","article-title":"Efficacy and safety of sitagliptin compared with dapagliflozin in people\u2009\u2265\u200965 years old with type 2 diabetes and mild renal insufficiency","volume":"11","author":"Raji","year":"2020","journal-title":"Diabetes Ther"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1659740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:52:06Z","timestamp":1767768726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1659740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":42,"alternative-id":["10.3389\/fendo.2025.1659740"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1659740","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1659740"}}